Your browser doesn't support javascript.
loading
A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer.
Tang, Stephen; Sethunath, Vidyalakshmi; Metaferia, Nebiyou Y; Nogueira, Marina F; Gallant, Daniel S; Garner, Emma R; Lairson, Lauren A; Penney, Christopher M; Li, Jiao; Gelbard, Maya K; Alaiwi, Sarah Abou; Seo, Ji-Heui; Hwang, Justin H; Strathdee, Craig A; Baca, Sylvan C; AbuHammad, Shatha; Zhang, Xiaoyang; Doench, John G; Hahn, William C; Takeda, David Y; Freedman, Matthew L; Choi, Peter S; Viswanathan, Srinivas R.
Afiliação
  • Tang S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Sethunath V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Metaferia NY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Nogueira MF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Gallant DS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Garner ER; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Lairson LA; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Penney CM; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Li J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Gelbard MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Alaiwi SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Hwang JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Strathdee CA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • AbuHammad S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Zhang X; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
  • Doench JG; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Takeda DY; Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Choi PS; Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology & Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: peter.choi@pennmedicine.upenn.edu.
  • Viswanathan SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02215, USA. Electronic address: srinivas.viswanathan@dfci.harvard.edu.
Cell Rep ; 38(8): 110417, 2022 02 22.
Article em En | MEDLINE | ID: mdl-35196489
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article